View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 23, 2019

Regular intake of aspirin could increase bleeding risk

A systematic review by King’s College London, King’s College Hospital and Imperial College London has revealed that frequent use of aspirin, to prevent heart attack and strokes, could increase the risk of major bleeding episodes by 50%.

A systematic review by King’s College London, King’s College Hospital and Imperial College London has revealed that frequent use of aspirin to prevent heart attack and strokes could increase the risk of major bleeding episodes by 50%.

The study analysed the outcomes from 13 clinical trials involving a total of more than 164,000 participants, according to Reuters. The participants did not have a known history of cardiovascular diseases.

During the studies, the team assessed the overall effects of regular intake of aspirin on patients. They also performed a follow-up after 12 months.

Findings showed that taking aspirin could lower the risk of cardiovascular events by 11%, while it was associated with 43% of major bleeding events, compared to patients who did not take the medicine.

In addition, around 250 patients required treatment with aspirin for five years to prevent a single heart attack, stroke or cardiovascular death.

“This study shows that while cardiovascular events may be reduced in these patients, these benefits are matched by an increased risk of major bleeding events.”

King’s College London cardiology academic clinical fellow Sean Zheng said: “This study demonstrates that there is insufficient evidence to recommend routine aspirin use in the prevention of heart attacks, strokes and cardiovascular deaths in people without cardiovascular disease.

“This study shows that while cardiovascular events may be reduced in these patients, these benefits are matched by an increased risk of major bleeding events.”

In September last year, Monash University in Australia announced initial results from the ASPREE clinical trial investigating the benefits and risks of low, daily doses of aspirin in healthy people aged over 70 years.

Being conducted in a total of 19,000 subjects in the US and Australia, the trial showed that 100mg aspirin did not significantly decrease the risk of a first heart attack or stroke.

However, taking the drug resulted in a 3.8% increase in the number of serious bleeding cases among participants taking aspirin, compared to 2.8% in the placebo arm.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology